– GERMANY, Bonn – NEUWAY Pharma announced today the appointment of Dr. Rudi Scherhag as Chief Operating Officer and Managing Director. Dr. Scherhag has extensive experience in managing various development projects from pre-clinical to registration in the pharmaceutical and biotech industry.
As planned, Dr. Scherhag will take over the managing director position from Dr. Stephan Rapp, who will focus on new projects and act as consultant and shareholder of NEUWAY.
Dr. Scherhag has made his most important professional step at Boehringer Mannheim/Roche, where he successfully managed the global development of its blockbuster product Epoetin beta. He also played a major role in the establishment of two companies. As a Member of the Executive Board at Heidelberg Pharma , Dr. Scherhag was responsible for project and business development. Before joining Neuway, he served as Managing Director at ImClone Systems International, a newly founded European clinical development organization of the US biotech company ImClone Systems Corp.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.